Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis
Primary Purpose
Erosive Osteoarthritis of the Hand
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Apremilast
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Erosive Osteoarthritis of the Hand focused on measuring EHOA
Eligibility Criteria
Inclusion Criteria:
- Must have at least two bone erosions detectable in conventional radiographs of the hands at the first carpo-metacarpal joint (CMC), proximal and/or distal interphalangeal joints
- Must have active disease at screening and randomization with at least two swollen and tender PIP and/or DIP joints; with the same two joints affected at both screening and randomization.
- Must have a patients self assessment of pain at baseline of at least 40% on a VAS
- Must have negative rheumatoid factor (RF) and anti-CCP antibody
- Must be able to adhere to the study visit schedule and other protocol requirements
- Male subjects (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with Females of Childbearing Potential (FCBP)while on study medication and for at least 28 days after taking the last dose of study medication
- Females of childbearing potential (FCBP) must have a negative urine pregnancy test at Screening and Baseline and must be willing to use one highly-effective form of birth control when engaging in reproductive sexual activity while on study medication and for at least 28 days after taking the last dose of study medication (§ A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).
Must meet the following laboratory criteria:
- Hemoglobin ≥ 9 g/dL
- Hematocrit ≥ 27%
- White blood cell (WBC) count ≥ 3000 /μL (≥ 3.0 X 109/L) and ≤ 14,000/μL (< 14 X 109/L)
- Platelets ≥ 100,000 /μL (≥ 100 X 109/L)
- Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
- Total bilirubin ≤ 2.0 mg/dL
- Aspartate transaminase (AST, SGOT]) and alanine transaminase(ALT, SGPT]) ≤ 1.5x upper limit of normal (ULN)
Exclusion criteria:
- History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases
- History of any clinically significant inflammatory disease other than EHOA, especially, but not limited to, rheumatoid arthritis or spondylarthropathies
- History or Diagnosis of Fibromyalgia
- Evidence of gout, pseudogout or hemochromatosis
- Any injury, medical or surgical procedure to the affected joint(s) that may interfere with evaluation of the target hand OA joint(s)
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Pregnant or lactating female
- History of active Mycobacterium tuberculosis infection within 3 years prior to the screening visit. Infections that occurred > 3 years prior to entry must have been effectively treated
- History of incompletely treated latent Mycobacterium tuberculosis infection (as indicated by a positive Purified Protein Derivative [PPD] skin test or in vitro test (QuantiFERON Gold®).
- History of infected joint or joint prosthesis within the past 5 years
- Any anti-inflammatory or immunosuppressive therapy for any condition including, but not limited to, glucocorticoids, methotrexate, sulfasalazine, leflunomide, chloroquine, hydroxychloroquine, gold compounds, parenteral corticosteroids, penicillamine, cyclosporine, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus and azathioprine within 35 days of randomization and throughout the study
- Use of NSAIDs within 35 days of randomization and throughout the study
- Intra-articular corticosteroids for the targeted joints within three months prior to randomization
- Intra-articular injection of hyaluronate for the targeted joints within six month prior to randomization
- Use of any investigational medication within 35 days prior to randomization or 5 half-lives if known (whichever is longer)
- Use of "nutraceuticals" and alternative medicine products, unless taken at a stable dose for a minimum of three month prior to randomization
- Any clinically significant abnormality on 12-lead ECG at screening as determined by the investigator
- History of malignancy within previous 5 years (except for treated basal-cell skin carcinoma and/or squamous-cell skin carcinoma)
- High-risk factor(s) for, or a history of, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus infection
- Have a known history of serious infections (eg, hepatitis, pneumonia, or pyelonephritis) in the previous 3 months Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results
- Have participated in this study before
- Patients who are underage or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 und Abs. 3 AMG).
- Patients who possibly are dependent on the sponsor or investigator
Sites / Locations
- Prof. G. Schett, University Hospital Erlangen
- Prof. Ulf Müller-Ladner, Kerckhoff-Klinik
- Prof. Matthias Schneider, Universitätsklinikum Düsseldorf, Klinik für Endokrinologie, Diabetologie und Rheumatologie
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Apremilast capsules
Placebo
Arm Description
Apremilast in 10 mg capsules
Outcomes
Primary Outcome Measures
Proportion of subjects in each treatment group who achieve a significant 50% improvement in AUSCAN Index at day 84 after treatment start compared with baseline
Proportion of subjects in each treatment group who achieve a significant 50% improvement in AUSCAN Index at day 84 after treatment start compared with baseline.
Secondary Outcome Measures
Absolute values and change from baseline of the Patient self Assessment score (VAS) from baseline, day 84 and day 168 as well as proportion of patients in each treatment group who achieve improvements
Patients self assessment of pain (VAS)
Change of the Physicians and Patients self assessment of global status (VAS)score from baseline, day 84 and day 168.
Physicians and Patients self assessment of global status (VAS)
Change of the HAQ score from baseline, day 84 and day 168 in each treatment group who achieve improvements
HAQ
Change of the SACRAH score from baseline, day 84 and day 168 in each treatment group who achieve improvements
SACRAH
Change of the duration of the joint stiffness from baseline, day 84 and day 168 in each treatment group who achieve improvements
Duration of joint stiffness
Change of swollen and tender joints from baseline compared to day 84 and day 168 in each treatment group.
Swollen and tender joint counts
Measuring radiology changes from baseline, day 84 and day 168 using the RAMRIS score in each treatment.
RAMRIS scoring system
Changes of the SF36 from baseline, day 84 and day 168 in each treatment group.
SF36
Full Information
NCT ID
NCT01200472
First Posted
April 8, 2010
Last Updated
October 18, 2013
Sponsor
University of Erlangen-Nürnberg Medical School
Collaborators
Celgene Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01200472
Brief Title
Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis
Official Title
A Phase 2, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel-group,Efficacy Study of Apremilast (CC-10004)in Subjects With Erosive Hand Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Erlangen-Nürnberg Medical School
Collaborators
Celgene Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
STUDY DESIGN:
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study in 30 patients with erosive osteoarthritis of interphalangeal joints. The study is composed of 4 phases: a pre-randomization phase for up to 35 days followed by a 91-day randomized, double-blind two arm treatment phase, followed by a 77-day open label treatment phase for all study participants and a 28-day observational follow-up phase. Efficacy of the double blind and open label phase will be assessed at study day 84 and 168 after treatment start respectively.
STUDY DURATION:
The study length will be approximately 231 days for individual patients. With approximately a 12 month recruitment period the study is planned to last from January 2010 until July 2011 (19 months).
STUDY OBJECTIVES:
The primary objective is to evaluate the 84-day efficacy of apremilast 20 mg twice per day [BID], subsequent to a 7-day dose titration, compared with placebo, for the treatment of the symptoms of erosive hand osteoarthritis. Further objectives are to evaluate the effects on pain, disease activity, structural damage, quality of life, safety and tolerability.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erosive Osteoarthritis of the Hand
Keywords
EHOA
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Apremilast capsules
Arm Type
Experimental
Arm Description
Apremilast in 10 mg capsules
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Apremilast
Intervention Description
Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo capsules identical to apremilast
Primary Outcome Measure Information:
Title
Proportion of subjects in each treatment group who achieve a significant 50% improvement in AUSCAN Index at day 84 after treatment start compared with baseline
Description
Proportion of subjects in each treatment group who achieve a significant 50% improvement in AUSCAN Index at day 84 after treatment start compared with baseline.
Time Frame
Day 84 after treatment start compared with baseline
Secondary Outcome Measure Information:
Title
Absolute values and change from baseline of the Patient self Assessment score (VAS) from baseline, day 84 and day 168 as well as proportion of patients in each treatment group who achieve improvements
Description
Patients self assessment of pain (VAS)
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Change of the Physicians and Patients self assessment of global status (VAS)score from baseline, day 84 and day 168.
Description
Physicians and Patients self assessment of global status (VAS)
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Change of the HAQ score from baseline, day 84 and day 168 in each treatment group who achieve improvements
Description
HAQ
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Change of the SACRAH score from baseline, day 84 and day 168 in each treatment group who achieve improvements
Description
SACRAH
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Change of the duration of the joint stiffness from baseline, day 84 and day 168 in each treatment group who achieve improvements
Description
Duration of joint stiffness
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Change of swollen and tender joints from baseline compared to day 84 and day 168 in each treatment group.
Description
Swollen and tender joint counts
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Measuring radiology changes from baseline, day 84 and day 168 using the RAMRIS score in each treatment.
Description
RAMRIS scoring system
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
Title
Changes of the SF36 from baseline, day 84 and day 168 in each treatment group.
Description
SF36
Time Frame
Day 84 and at day 168 after treatment start compared with Baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must have at least two bone erosions detectable in conventional radiographs of the hands at the first carpo-metacarpal joint (CMC), proximal and/or distal interphalangeal joints
Must have active disease at screening and randomization with at least two swollen and tender PIP and/or DIP joints; with the same two joints affected at both screening and randomization.
Must have a patients self assessment of pain at baseline of at least 40% on a VAS
Must have negative rheumatoid factor (RF) and anti-CCP antibody
Must be able to adhere to the study visit schedule and other protocol requirements
Male subjects (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with Females of Childbearing Potential (FCBP)while on study medication and for at least 28 days after taking the last dose of study medication
Females of childbearing potential (FCBP) must have a negative urine pregnancy test at Screening and Baseline and must be willing to use one highly-effective form of birth control when engaging in reproductive sexual activity while on study medication and for at least 28 days after taking the last dose of study medication (§ A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).
Must meet the following laboratory criteria:
Hemoglobin ≥ 9 g/dL
Hematocrit ≥ 27%
White blood cell (WBC) count ≥ 3000 /μL (≥ 3.0 X 109/L) and ≤ 14,000/μL (< 14 X 109/L)
Platelets ≥ 100,000 /μL (≥ 100 X 109/L)
Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
Total bilirubin ≤ 2.0 mg/dL
Aspartate transaminase (AST, SGOT]) and alanine transaminase(ALT, SGPT]) ≤ 1.5x upper limit of normal (ULN)
Exclusion criteria:
History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases
History of any clinically significant inflammatory disease other than EHOA, especially, but not limited to, rheumatoid arthritis or spondylarthropathies
History or Diagnosis of Fibromyalgia
Evidence of gout, pseudogout or hemochromatosis
Any injury, medical or surgical procedure to the affected joint(s) that may interfere with evaluation of the target hand OA joint(s)
Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
Pregnant or lactating female
History of active Mycobacterium tuberculosis infection within 3 years prior to the screening visit. Infections that occurred > 3 years prior to entry must have been effectively treated
History of incompletely treated latent Mycobacterium tuberculosis infection (as indicated by a positive Purified Protein Derivative [PPD] skin test or in vitro test (QuantiFERON Gold®).
History of infected joint or joint prosthesis within the past 5 years
Any anti-inflammatory or immunosuppressive therapy for any condition including, but not limited to, glucocorticoids, methotrexate, sulfasalazine, leflunomide, chloroquine, hydroxychloroquine, gold compounds, parenteral corticosteroids, penicillamine, cyclosporine, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus and azathioprine within 35 days of randomization and throughout the study
Use of NSAIDs within 35 days of randomization and throughout the study
Intra-articular corticosteroids for the targeted joints within three months prior to randomization
Intra-articular injection of hyaluronate for the targeted joints within six month prior to randomization
Use of any investigational medication within 35 days prior to randomization or 5 half-lives if known (whichever is longer)
Use of "nutraceuticals" and alternative medicine products, unless taken at a stable dose for a minimum of three month prior to randomization
Any clinically significant abnormality on 12-lead ECG at screening as determined by the investigator
History of malignancy within previous 5 years (except for treated basal-cell skin carcinoma and/or squamous-cell skin carcinoma)
High-risk factor(s) for, or a history of, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus infection
Have a known history of serious infections (eg, hepatitis, pneumonia, or pyelonephritis) in the previous 3 months Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results
Have participated in this study before
Patients who are underage or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 und Abs. 3 AMG).
Patients who possibly are dependent on the sponsor or investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georg Schett, MD
Organizational Affiliation
University Hospital Erlangen, Department of Internal Medicine 3, Rheumatology and Clinical Immunology
Official's Role
Study Director
Facility Information:
Facility Name
Prof. G. Schett, University Hospital Erlangen
City
Erlangen
State/Province
Bavaria
ZIP/Postal Code
91054
Country
Germany
Facility Name
Prof. Ulf Müller-Ladner, Kerckhoff-Klinik
City
Bad Nauheim
ZIP/Postal Code
61231
Country
Germany
Facility Name
Prof. Matthias Schneider, Universitätsklinikum Düsseldorf, Klinik für Endokrinologie, Diabetologie und Rheumatologie
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis
We'll reach out to this number within 24 hrs